Valneva
Ingmar Stoll has extensive experience in the field of laboratory animal facilities and quality control, currently serving as the Head Laboratory Animal Facility at Valneva since August 2013, where previous roles included Laboratory Animal Facilities Manager and Senior Specialist Quality Control. Prior to Valneva, Stoll worked at Intercell AG from November 2006 to August 2013, holding positions such as GMP Group Leader Quality Control and Lab Manager in Research and Development. Ingmar's career also includes a role as Lab Manager in Research and Development at Octagene Biomedical Laboratories from 2000 to 2003. A graduate of Naturwissenschaftliches Technikum Landau (NTK), Stoll's expertise spans areas such as gene therapy and haemophilia.
This person is not in any teams
This person is not in any offices
Valneva
2 followers
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.